Skip to content

NASDAQ · mid · thesis board

GPCR Structure Therapeutics

Oral GLP-1 receptor agonist

View race

Thesis

Editorial summary — not a primary filing

Oral small-molecule incretin approach; differentiation vs injectables is the thesis.

Next gate

2026-12-20EstimatedPh2 readout

Phase 2b readout

129 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~21 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~782d)100%
Days to gate (129d)16%
Show math

$720M cash ÷ $28M/mo burn ≈ 782 days. Source: curated SEC quarter figures.

Cash $720M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
NVOPh3okLLYPh3okAMGNPh3ok

Risks

  • Efficacy vs injectables
  • GI tolerability
  • Capital for Phase 3
  • Crowded oral race

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT06085729as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01